BridgeMD
Impact of oxygen therapy in exertion in physical activity of patients with fibrotic intertitial lung disease with exertional hypoxemia (AFOX study)
EU CTIS ID: 2023-510440-20-00
What this study is testing
Feasibility study that evaluates the impact of oxygen therapy on exertion in physical activity measured by accelerometer (steps/day) in patients with fibrotic ILD with exertional hypoxemia (minimum SpO2 ≤ 88% in the 6MWT), at one month and after three months of follow-up.
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Patients aged greater than or equal to 18 years.
- Patients with a diagnosis of fibrotic ILD, defined by the presence of peripheral reticulation, traction bronchiectasis, volume loss and/or presence of “honeycombing” on high-resolution chest CT (HRCT).
- Patients with minimum SpO2 ≤ 88% in the 6MWT performed in room air.
- Stability of respiratory symptoms two weeks prior to inclusion.
You likely can't join if
- SpO2 ≤ 93% at rest
- Coexistence of other respiratory diseases such as COPD or asthma
- Moderate-severe pulmonary hypertension measured by transthoracic echocardiography
- Cardiological, osteo-articular or cognitive comorbidities that prevent correct performance of the 6MWT or a correct measurement of daily physical activity
- Diagnosis of neoplasia in active treatment
- Hospital admission 2 months prior to inclusion in the study
See the full eligibility criteria
- Patients aged greater than or equal to 18 years.
- Patients with a diagnosis of fibrotic ILD, defined by the presence of peripheral reticulation, traction bronchiectasis, volume loss and/or presence of “honeycombing” on high-resolution chest CT (HRCT).
- Patients with minimum SpO2 ≤ 88% in the 6MWT performed in room air.
- Stability of respiratory symptoms two weeks prior to inclusion.
- SpO2 ≤ 93% at rest
- Coexistence of other respiratory diseases such as COPD or asthma
- Moderate-severe pulmonary hypertension measured by transthoracic echocardiography
- Cardiological, osteo-articular or cognitive comorbidities that prevent correct performance of the 6MWT or a correct measurement of daily physical activity
- Diagnosis of neoplasia in active treatment
- Hospital admission 2 months prior to inclusion in the study
- Current smoker
- Being in a current pulmonary rehabilitation program
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.